Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT07145125 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT07145125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07145125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma
Lead sponsor
University Hospital, Bordeaux
Phase
Observational
Overall status
Completed
Start date
February 1, 2025
Completion date
September 30, 2025
Enrollment
222 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory hodgkin lymphoma